Lyra Therapeutics Stock Today
| LYRA Stock | USD 0.18 0 1.67% |
Performance0 of 100
| Odds Of DistressOver 73
|
Lyra Therapeutics is trading at 0.183 as of the 30th of January 2025, a 1.67 percent increase since the beginning of the trading day. The stock's open price was 0.18. Lyra Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of May 2020 | Category Healthcare | Classification Health Care |
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. Lyra Therapeutics, Inc. The company has 65.46 M outstanding shares of which 2.13 M shares are now shorted by private and institutional investors with about 1.09 trading days to cover. More on Lyra Therapeutics
Moving together with Lyra Stock
| 0.64 | JNJ | Johnson Johnson | PairCorr |
| 0.64 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.66 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
Moving against Lyra Stock
| 0.6 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lyra Stock Highlights
| President CEO | Maria Palasis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLyra Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lyra Therapeutics' financial leverage. It provides some insight into what part of Lyra Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lyra Therapeutics (LYRA) is traded on NASDAQ Exchange in USA. It is located in 480 Arsenal Way, Watertown, MA, United States, 02472 and employs 88 people. Lyra Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.93 M. Lyra Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 65.46 M outstanding shares of which 2.13 M shares are now shorted by private and institutional investors with about 1.09 trading days to cover.
Lyra Therapeutics currently holds about 120.67 M in cash with (63.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Lyra Therapeutics Probability Of Bankruptcy
Ownership AllocationLyra Therapeutics maintains a total of 65.46 Million outstanding shares. Over half of Lyra Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Lyra Ownership Details
Lyra Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2024-09-30 | 460.3 K | |
| Two Sigma Investments Llc | 2024-09-30 | 282.5 K | |
| Everhart Financial Group, Inc. | 2024-09-30 | 252.7 K | |
| Boothbay Fund Management, Llc | 2024-09-30 | 232.7 K | |
| Northern Trust Corp | 2024-09-30 | 183.3 K | |
| Exoduspoint Capital Management, Lp | 2024-09-30 | 159.2 K | |
| New York State Common Retirement Fund | 2024-09-30 | 154.8 K | |
| Bank Of Montreal | 2024-09-30 | 119.4 K | |
| Bmo Capital Markets Corp. | 2024-09-30 | 119.4 K | |
| Perceptive Advisors Llc | 2024-09-30 | 12.8 M | |
| Citadel Advisors Llc | 2024-09-30 | 4.8 M |
Lyra Therapeutics Historical Income Statement
Lyra Stock Against Markets
Lyra Therapeutics Corporate Management
| Dr Roberts | CoFounder | Profile | |
| Corinne Noyes | Senior Development | Profile | |
| Donald MBA | Advisor | Profile | |
| Gloria Cosgrove | Senior Quality | Profile | |
| Ellen Cavaleri | Senior Communications | Profile | |
| Richard MD | Chief Officer | Profile | |
| Ronan JD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share | Quarterly Revenue Growth (0.64) | Return On Assets | Return On Equity |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.